Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT) - Scorecard - MDSpire

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • By

  • Maohui Chen

  • Yizhou Huang

  • Shuliang Zhang

  • Cheng Chen

  • Taidui Zeng

  • Hongmu Li

  • Zhenyuan Yang

  • Chuanquan Lin

  • Wei Li

  • Benhua Xu

  • Chun Chen

  • Bin Zheng

  • March 9, 2026

  • 0 min

Share

Clinical Scorecard: Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

At a Glance

CategoryDetail
ConditionLocally advanced esophageal squamous cell carcinoma (ESCC)
Key MechanismsNeoadjuvant camrelizumab plus radiotherapy enhances antitumor immunity while minimizing chemotherapy-related toxicity.
Target PopulationAdults aged 18–75 years with histologically confirmed ESCC, clinical stage T2–3 N0 M0 or T2–3 N + M0.
Care SettingSingle-arm phase II trial conducted at Fujian Medical University Union Hospital, China.

Key Highlights

  • High rates of major pathologic response (MPR) and R0 resection observed.
  • Very low rates of high-grade toxicity reported.
  • Generally mild postoperative complications noted.
  • Supports further evaluation of chemotherapy-sparing regimens.
  • Potential treatment option for patients ineligible for standard chemotherapy.

Guideline-Based Recommendations

Diagnosis

  • Histologically confirm ESCC.
  • Classify as clinical stage T2–3 N0 M0 or T2–3 N + M0.

Management

  • Consider neoadjuvant camrelizumab plus radiotherapy as an alternative to traditional chemoradiotherapy.

Monitoring & Follow-up

  • Monitor for adverse events and treatment feasibility throughout the study.

Risks

  • Potential for distant recurrence despite treatment.

Patient & Prescribing Data

Adults aged 18–75 years with ECOG performance status of 0 or 1.

Chemotherapy-sparing approach may benefit elderly or frail patients vulnerable to chemotherapy-related toxicity.

Clinical Best Practices

  • Utilize a multidisciplinary team for monitoring patient safety and adverse events.
  • Implement a two-stage design for clinical trials to assess efficacy and safety.

References

Original Source(s)

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • by Maohui Chen, Yizhou Huang, Shuliang Zhang, Cheng Chen, Taidui Zeng, Hongmu Li, Zhenyuan Yang, Chuanquan Lin, Wei Li, Benhua Xu, Chun Chen, Bin Zheng

  • March 9, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer